Fecal Calprotectin Assay at an Early Stage of Treatment Can Be Used as a Surrogate Marker to Predict Clinical Remission and Mucosal Healing in Pediatric Crohn’s Disease

PURPOSE: This study evaluated the predictive role of fecal calprotectin (FC) measured at an early stage of treatment for monitoring clinical remission (CR) after six months and endoscopic remission (ER) after one year of treatment in pediatric Crohn’s disease (CD). METHODS: This retrospective study...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Yeoun Joo, Park, Jae Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482829/
https://www.ncbi.nlm.nih.gov/pubmed/36148291
http://dx.doi.org/10.5223/pghn.2022.25.5.396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9482829/
https://www.ncbi.nlm.nih.gov/pubmed/36148291
http://dx.doi.org/10.5223/pghn.2022.25.5.396

Ejemplares similares